Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 55 participantsLow